Stojnev, Slavica; Golubović, Mlađan; Babović, Petar
March 2010
Acta Medica Medianae;Mar2010, Vol. 49 Issue 1, p59
Academic Journal
TP53 tumor suppressor gene mutations are the most frequent genetic alterations in human cancer affecting a specific gene. The occurrence of TP53 mutations is considerably influenced by cancer-initiating events, such as DNA damage, the aftermath of which is the promotion of cancer development through the loss of anti-proliferative activities, including apoptosis and cellular senescence. Over 27.000 TP53 gene mutations have been discovered and found in more than 50% of human cancers. The most frequent alterations are the point mutations with a single base substitution in gene segment encoding for DNA-binding domaine of p53 molecule, leading to the production of mutant protein that differs from the wild-type protein by one amino acid (missense mutations) usually causing the change in tertiary structure of gene product, thus preventing p53 to bind to DNA and activate transcription of target genes. The result of the mutations may also be the proteins with new, abnormal functions, and the ability to modulate expression of genes responsible for neoangiogenesis, resistance to chemotherapeutics and prevention of tumor initiation and promotion. In such circumstances, not only the mutant TP53 loses its tumor suppressive function, but acquires oncogenic potential and becomes an active participant in the neoplastic transformation of the cell. Vast heterogeneity of mutations and methodological approaches in p53 status assessment represent the main difficulties in rapid and effective integration of basic p53 research into clinical practice.


Related Articles

  • Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data. Kumar, Runjun D.; Searleman, Adam C.; Swamidass, S. Joshua; Griffith, Obi L.; Bose, Ron // Bioinformatics;11/15/2015, Vol. 31 Issue 22, p3561 

    Motivation: Several tools exist to identify cancer driver genes based on somatic mutation data. However, these tools do not account for subclasses of cancer genes: oncogenes, which undergo gain-of-function events, and tumor suppressor genes (TSGs) which undergo loss-of-function. A method which...

  • Wip-ing out cancer. Bernards, René // Nature Genetics;Apr2004, Vol. 36 Issue 4, p319 

    Reports on a study of encoding of Wip1 phosphatase by an oncogene that is enlarged in several forms of human cancer. Combination of activating mutations in growth-stimulatory genes and inactivating mutations in growth-inhibitory genes resulting in cancer; Wip1 as a good strategy to cure certain...

  • Mutations and polymorphisms in TP53 gene—an overview on the role in colorectal cancer. Naccarati, A.; Polakova, V.; Pardini, B.; Vodickova, L.; Hemminki, K.; Kumar, R.; Vodicka, P. // Mutagenesis;Mar2012, Vol. 27 Issue 2, p211 

    A functionally normal TP53 is essential to protect organisms from developing cancer. Somatic mutations in the gene represent one of the highest recurring perturbations in human tumours, including colorectal cancer (CRC). However, the variegated phenotype of wide spectrum of somatic mutations in...

  • Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer. Li, D; Zhang, Y; Xie, Y; Xiang, J; Zhu, Y; Yang, J // Cancer Gene Therapy;Apr2013, Vol. 20 Issue 4, p251 

    DNA-damaging anticancer drug cisplatin (cis-diamminedichloroplatinum) (DDP)-based chemotherapy is the mainstay and standard treatment for small-cell lung cancer (SCLC). However, frequent relapse and chemoresistance of SCLC remains a significant therapeutic hurdle. Tumor suppressor phosphatase...

  • Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Falck, Jacob; Lukas, Claudia; Protopopova, Marina; Lukas, Jiri; Selivanova, Galina; Bartek, Jiri // Oncogene;9/6/2001, Vol. 20 Issue 39, p5503 

    Recent evidence identified a genetic and functional link between Chk2 kinase and p53 as a candidate genome integrity checkpoint and a tumour suppressor pathway. Here we report that in human cells, Chk2 and p53 form protein–protein complexes whose abundance increased upon DNA damage, and...

  • Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Fonsatti, Ester; Altomonte, Maresa; Nicotra, Maria Rita; Natali, Pier Giorgio; Maio, Michele // Oncogene;9/29/2003 Review, Vol. 22 Issue 42, p6557 

    Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane glycoprotein mainly expressed on endothelial cells and overexpressed on tumor-associated vascular endothelium, which...

  • Differential effects of p63 mutants on transactivation of p53 and/or p63 responsive genes. Khokhar, Shama K.; Kommagani, Ramakrishna; Kadakia, Madhavi P. // Cell Research;Oct2008, Vol. 18 Issue 10, p1061 

    p63, known to play a role in development, has more recently also been implicated in cancer progression. Mutations in p63 have been shown to be responsible for several human developmental diseases. Differential splicing of the p63 gene gives rise to p63 isoforms, which can act either as tumor...

  • BRCA- 1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Foedermayr, Mathilde; Sebesta, Miriam; Rudas, Margaretha; Berghoff, Anna; Promberger, Regina; Preusser, Matthias; Dubsky, Peter; Fitzal, Florian; Gnant, Michael; Steger, Guenther; Weltermann, Ansgar; Zielinski, Christoph; Zach, Otto; Bartsch, Rupert // Cancer Chemotherapy & Pharmacology;Apr2014, Vol. 73 Issue 4, p771 

    Introduction: Triple-negative breast cancer (TNBC) patients without pathological complete response (pCR) to neoadjuvant chemotherapy have an unfavourable prognosis. TNBC harbouring BRCA- 1 germline mutations may be less responsive to taxanes, while sensitivity to DNA-damaging agents is retained....

  • Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Pardo, F. S.; Hsu, D. W.; Zeheb, R.; Efird, J. T.; Okunieff, P. G.; Malkin, D. M. // British Journal of Cancer;11/1/2004, Vol. 91 Issue 9, p1678 

    Abnormalities of the p53 tumor-suppressor gene are found in a significant proportion of astrocytic brain tumours. We studied tumour specimens from 74 patients evaluated over 20 years at the Massachusetts General Hospital, where clinical outcome could be determined and sufficient pathologic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics